BIOMECHANICAL MARKERS OF GAIT IMPAIRMENT PROGRESSION IN PARKINSON`S DISEASE
Abstract
Aim: to conduct a comparative analysis of clinical and biomechanical parameters of gait in patients at various stages of Parkinson`s Disease (PD).
Materials and methods. 171 patients with PD were examined, the median age was 67.5 ± 7.92 years. Assessment of gait impairment (GI) was conducted with computerized protocol Diers pedogait. Statistical processing was performed using Statistica 10 and Microsoft Excel 2016.
Results. When patients were divided into groups according to the stage, statistically signifi cant diff erences were obtained in terms of foot rotation angle, decrease in stride length, velocity, stride time and cadence. With a disease duration of up to 2 years and from 2 to 5 years, diff erences were found in the average time of a single step and the length of a step. With a disease duration of 5–10 years Tinetti balance tests (TBT) indicated signifi cant progression of GI, as well as the following parameters: stride length, track width, velocity, depending on lateralization — duration of the pre-swing phase, single stride time.
Conclusion. Diers pedogait is an eff ective method for detecting early sings of PD progression on the stage when clinical scales are reliable, which will allow an early correction of therapy and rehabilitation of patients. A broader introduction of biomechanical methods for examination of gait impairment into practice both in neurological departments and in rehabilitation institutions is needed.
About the Authors
E. V. Gracheva
Federal State Budgetary Scientifi c Institution «Institute of Experimental Medicine»
Russian Federation
Russian Federation
postgraduate student
St. Petersburg
I. V. Miliukhina
Federal State Budgetary Scientifi c Institution «Institute of Experimental Medicine»,
Pavlov First Saint Petersburg State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
P. V. Lebedev
Pavlov First Saint Petersburg State Medical University
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
S. G. Tsikunov
Federal State Budgetary Scientifi c Institution «Institute of Experimental Medicine»
Russian Federation
St. Petersburg
Russian Federation
St. Petersburg
References
1. Galna B., Lord S., Burn D.J., Rochester L. Progression of gait dysfunction in incident Parkinson’s disease: impact of medication and phenotype. Movement Disorders. 2015;30(3):359–367. https://doi.org/10.1002/mds.26110.
2. Sveinbjornsdottir S. The clinical symptoms of Parkinson’s disease. Journal of neurochemistry. 2016;139:318–324. https://doi.org/10.1111/jnc.13691.
3. Miliukhina I.V., Gracheva E.V. Modern views on gait impairment in Parkinsons disease and its correction. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 2018;118(6):96–101. (in Russian) https://doi.org/10.17116/jnevro20181186196.
4. Tinetti М.Е. Performance‐oriented assessment of mobility problems in elderly patients. Journal of the American Geriatrics Society. 1986;34(2):119–126.
5. Podsiadlo D., Richardson S. The timed «Up & Go»: a test of basic functional mobility for frail elderly persons. Journal of the American geriatrics Society. 1991;39(2):142–148.
6. Wrisley D.M., Marchetti G.F., Kuharsky D.K., Whitney S.L. Reliability, internal consistency, and validity of data obtained with the functional gait assessment. Physical therapy. 2004;84(10): 906–918.
7. Behrman A.L., Light K.E., Miller G.M. Sensitivity of the Tinetti Gait Assessment for detecting change in individuals with Parkinson’s disease. Clinical Rehabilitation. 2002;16:399–405.
8. Grimbergen Y.A.M., Munneke M., Bloem B.R. Falls in Parkinson’s disease. Current opinion in neurology. 2004;17(4):405–415.
9. Pistacchi M., Gioulis M., Sanson F., De Giovannini E., Filippi G., Rossetto F., Marsala S.Z. Gait analysis and clinical correlations in early Parkinson’s disease. Functional neurology. 2017;32(1):28. https://doi.org/10.11138/FNeur/2017.32.1.028.
10. Schlachetzki J.C.M., Marxreiter J.B.F., Gossler J., Kohl Z., Reinfelder S., Gassner H., et al. Wearable sensors objectively measure gait parameters in Parkinson’s disease. PloS one. 2017;12(10):e0183989. https://doi.org/10.1371/journal.pone.0183989.
11. Wang X., Ristic-Durrant D., Spranger M., Gräser A. Gait assessment system based on novel gait variability measures. Rehabilitation Robotics (ICORR) 2017 International Conference on IEEE. 2017;467–472. https://doi.org/10.1109/ICORR.2017.8009292.
12. Opara J., Malecki A., Malecka E., Socha T. Motor assessment in Parkinsons disease. Annals of Agricultural and Environmental Medicine. 2017;24(3):411–415. https://doi.org/10.5604/12321966.1232774.
13. Vervoort G., Bengevoord A., Nackaerts E., Heremans E., Vandenberghe W., Nieuwboer A. Distal motor defi cit contributions to postural instability and gait disorder in Parkinson’s disease. Behavioural brain research. 2015;287:1–7. https://doi.org/10.1016/j.bbr.2015.03.026.
14. Postuma R.B., Berg D., Stern M., Poewe W., Olanow C.W., Oertel W. et al. MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders. 2015;30(12):1591–1601. https://doi.org/10.1002/mds.26424.
15. Hoehn M., Yahr M.D. Parkinsonism: onset, progression and mortality. Neurology. 1967;(15):427–442.
16. Iijima M., Mitoma H., Uchiyama S., Kitagawa K. Long-term Monitoring gait analysis using a wearable device in daily lives of patients with Parkinson’s Disease: The effi cacy of selegiline hydrochloride for gait disturbance. Frontiers in Neurology.
17. 2017;8:542. https://doi.org/10.3389/fneur.2017.00542.
18. Hobert M.A., Nussbaum S., Heger T., Berg D., Maetzler W., Heinzel S. Progressive gait defi cits in Parkinson’s disease: A wearable-based biannual 5-year prospective study. Frontiers in Aging Neuroscience. 2019;11:22. https://doi.org/10.3389/fnagi.2 019.00022.
Review
For citations:
Gracheva E.V., Miliukhina I.V., Lebedev P.V., Tsikunov S.G. BIOMECHANICAL MARKERS OF GAIT IMPAIRMENT PROGRESSION IN PARKINSON`S DISEASE. Russian neurological journal. 2019;(4):16-22. (In Russ.)
Views:
701
Email this article 